Premium
Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program
Author(s) -
Houghton Peter J.,
Kurmasheva Raushan T.,
Kolb E. Anders,
Wu Jianrong,
Gorlick Richard,
Maris John M.,
Smith Malcolm A.
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24756
Subject(s) - hepatocyte growth factor , medicine , autocrine signalling , antibody , cancer research , growth factor , immunology , pharmacology , receptor
TAK‐701 is a humanized antibody that binds hepatocyte growth factor (HGF), thus suppressing c‐Met transduced signaling and c‐Met dependent proliferation and migration of tumor cells. Six childhood solid tumor xenografts were selected for evaluating TAK‐701 based on immunochemical detection of HGF/c‐Met autocrine signaling [i.e., pMet(Tyr1349) and HGF positive]. TAK‐701 was tested using a dose of 30 mg/kg administered by the intraperitoneal (IP) route twice weekly for 4 weeks. TAK‐701 did not induce significant differences in EFS distribution in treated tumors compared to control tumors. Objective responses were not observed in any of the tested solid tumor xenografts. Pediatr Blood Cancer 2014;61:380–382. © 2013 Wiley Periodicals, Inc.